Search

Your search keyword '"Hoffmann, Ethan"' showing total 123 results
Start Over Author "Hoffmann, Ethan"
123 results on '"Hoffmann, Ethan"'

3. Pharmacological characterization of SAGE‐718, a novel positive allosteric modulator of N‐methyl‐d‐aspartate receptors.

Author

Beckley, Jacob T., Aman, Teresa K., Ackley, Michael A., Kazdoba, Tatiana M., Lewis, Michael C., Smith, Anne C., Farley, Brandon J., Dai, Jing, Deats, Wayne, Hoffmann, Ethan, Robichaud, Albert J., Doherty, James J., and Quirk, Michael C.

Subjects
GABA receptors, METHYL aspartate receptors, MEDIUM spiny neurons, EXCITATORY postsynaptic potential, EPILEPTIFORM discharges, STEROID receptors
Abstract

Background and Purpose: Select neuroactive steroids tune neural activity by modulating excitatory and inhibitory neurotransmission, including the endogenous cholesterol metabolite 24(S)‐hydroxycholesterol (24(S)‐HC), which is an N‐methyl‐d‐aspartate (NMDA) receptor positive allosteric modulator (PAM). NMDA receptor PAMs are potentially an effective pharmacotherapeutic strategy to treat conditions associated with NMDA receptor hypofunction. Experimental Approach: Using in vitro and in vivo electrophysiological recording experiments and behavioural approaches, we evaluated the effect of SAGE‐718, a novel neuroactive steroid NMDA receptor PAM currently in clinical development for the treatment of cognitive impairment, on NMDA receptor function and endpoints that are altered by NMDA receptor hypoactivity and assessed its safety profile. Key Results: SAGE‐718 potentiated GluN1/GluN2A‐D NMDA receptors with equipotency and increased NMDA receptor excitatory postsynaptic potential (EPSP) amplitude without affecting decay kinetics in striatal medium spiny neurons. SAGE‐718 increased the rate of unblock of the NMDA receptor open channel blocker ketamine on GluN1/GluN2A in vitro and accelerated the rate of return on the ketamine‐evoked increase in gamma frequency band power, as measured with electroencephalogram (EEG), suggesting that PAM activity is driven by increased channel open probability. SAGE‐718 ameliorated deficits due to NMDA receptor hypofunction, including social deficits induced by subchronic administration of phencyclidine, and behavioural and electrophysiological deficits from cholesterol and 24(S)‐HC depletion caused by 7‐dehydrocholesterol reductase inhibition. Finally, SAGE‐718 did not produce epileptiform activity in a seizure model or neurodegeneration following chronic dosing. Conclusions and Implications: These findings provide strong evidence that SAGE‐718 is a neuroactive steroid NMDA receptor PAM with a mechanism that is well suited as a treatment for conditions associated with NMDA receptor hypofunction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Pharmacological characterization of SAGE‐718, a novel positive allosteric modulator of N‐methyl‐d‐aspartate receptors

Author

Beckley, Jacob T., primary, Aman, Teresa K., additional, Ackley, Michael A., additional, Kazdoba, Tatiana M., additional, Lewis, Michael C., additional, Smith, Anne C., additional, Farley, Brandon J., additional, Dai, Jing, additional, Deats, Wayne, additional, Hoffmann, Ethan, additional, Robichaud, Albert J., additional, Doherty, James J., additional, and Quirk, Michael C., additional

Published
2023
Full Text
View/download PDF

7. To Reconstruct or Deconstruct? A Fundamental Question for the Psychology of Men and Masculinities.

Author

Hoffmann, Ethan and Addis, Michael E.

Subjects
*MASCULINITY, *COGNITIVE restructuring therapy, *POSITIVE psychology, *PSYCHOLOGY of men, *SOCIAL change, *SOCIAL norms, *PSYCHOLOGY, *PUBLIC health, *CONCEPTUAL structures, *SOCIAL skills, *PHILOSOPHY, *PSYCHOTHERAPY
Abstract

Efforts at social change have long been central to the psychological study of men and masculinities (PSMM) as a field. However, these efforts have been hampered by the absence of a coherent, unifying philosophical framework linking science to social practice or explicitly articulated guiding values. In this article, we argue that current social change efforts in PSMM can be characterized as attempts to either reconstruct or deconstruct masculinities. Reconstruction consists of attempts to modify or create more prosocial meanings of masculinities. Deconstruction, in contrast, consists of attempts to reduce or attenuate the psychological impact of masculinities on human behavior. We describe their practical application and review research support for each approach—including relevant recent clinical science research on cognitive restructuring and cognitive defusion. We then present functional contextualism as a coherent philosophy linking science to social practice that can be used by researchers and clinicians to evaluate when to pursue reconstructionist and/or deconstructionist approaches. We provide psychotherapy and public health campaign case examples to illustrate how researchers and clinicians might use a functional contextualist framework to evaluate the merits of reconstructionist and deconstructionist approaches, before closing by suggesting directions for future research. Public Significance Statement: This article describes two different approaches to science and practice focused on masculinities: efforts to reconstruct masculinities and efforts to deconstruct masculinities. The authors argue that the utility of these approaches is context-dependent and requires clarifying philosophical assumptions and guiding values. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Supplementary Table S1 from Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

Author

Thress, Kenneth, primary, MacIntyre, Terry, primary, Wang, Haiyun, primary, Whitston, Dave, primary, Liu, Zhong-Ying, primary, Hoffmann, Ethan, primary, Wang, Tao, primary, Brown, Jeffrey L., primary, Webster, Kevin, primary, Omer, Charles, primary, Zage, Peter E., primary, Zeng, Lizhi, primary, and Zweidler-McKay, Patrick A., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Fig. S3 from Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

Author

Thress, Kenneth, primary, MacIntyre, Terry, primary, Wang, Haiyun, primary, Whitston, Dave, primary, Liu, Zhong-Ying, primary, Hoffmann, Ethan, primary, Wang, Tao, primary, Brown, Jeffrey L., primary, Webster, Kevin, primary, Omer, Charles, primary, Zage, Peter E., primary, Zeng, Lizhi, primary, and Zweidler-McKay, Patrick A., primary

Published
2023
Full Text
View/download PDF

12. SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment

Author

Hill, Matthew D., primary, Blanco, Maria-Jesus, additional, Salituro, Francesco G., additional, Bai, Zhu, additional, Beckley, Jacob T., additional, Ackley, Michael A., additional, Dai, Jing, additional, Doherty, James J., additional, Harrison, Boyd L., additional, Hoffmann, Ethan C., additional, Kazdoba, Tatiana M., additional, Lanzetta, David, additional, Lewis, Michael, additional, Quirk, Michael C., additional, and Robichaud, Albert J., additional

Published
2022
Full Text
View/download PDF

16. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator

Author

Althaus, Alison L., primary, Ackley, Michael A., additional, Belfort, Gabriel M., additional, Gee, Steven M., additional, Dai, Jing, additional, Nguyen, David P., additional, Kazdoba, Tatiana M., additional, Modgil, Amit, additional, Davies, Paul A., additional, Moss, Stephen J., additional, Salituro, Francesco G., additional, Hoffmann, Ethan, additional, Hammond, Rebecca S., additional, Robichaud, Albert J., additional, Quirk, Michael C., additional, and Doherty, James J., additional

Published
2020
Full Text
View/download PDF

20. Neuroactive Steroid N-Methyl-d-aspartate Receptor Positive Allosteric Modulators: Synthesis, SAR, and Pharmacological Activity

Author

La, Daniel S., primary, Salituro, Francesco G., additional, Martinez Botella, Gabriel, additional, Griffin, Andrew M., additional, Bai, Zhu, additional, Ackley, Michael A., additional, Dai, Jing, additional, Doherty, James J., additional, Harrison, Boyd L., additional, Hoffmann, Ethan C., additional, Kazdoba, Tatiana M., additional, Lewis, Michael C., additional, Quirk, Michael C., additional, and Robichaud, Albert J., additional

Published
2019
Full Text
View/download PDF

23. Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus

Author

Noh, Radzi M., Venkatasubramanian, Sowmya, Daga, Shruti, Langrish, Jeremy, Mills, Nicholas L., Lang, Ninian N., Hoffmann, Ethan, Waterhouse, Brian, Newby, David E., and Frier, Brian M.

Subjects
lipids, cardiovascular risk, sirtuins, SIRT-1 activator, type 2 diabetes mellitus, Journal Article, platelet activation, weight loss, Basic and Translational Research, endothelial dysfunction
Abstract

Background: The cardiometabolic effects of SRT2104,\ud a novel SIRT1 activator, were investigated in people with\ud type 2 diabetes mellitus (T2DM).\ud Methods: Fifteen adults with T2DM underwent a\ud randomised, double-blind, placebo-controlled cross-over\ud trial and received 28 days of oral SRT2104 (2.0 g/day)\ud or placebo. Forearm vasodilatation (measured during\ud intrabrachial bradykinin, acetylcholine and sodium\ud nitroprusside infusions) as well as markers of glycaemic\ud control, lipid profile, plasma fibrinolytic factors, and\ud markers of platelet-monocyte activation, were measured\ud at baseline and at the end of each treatment period.\ud Results: Lipid profile and platelet-monocyte\ud activation were similar in both treatment arms\ud (p>0.05 for all). Forearm vasodilatation was\ud similar on exposure to acetylcholine and sodium\ud nitroprusside (p>0.05,respectively). Bradykinin-induced\ud vasodilatation was less during treatment with SRT2104\ud versus placebo (7.753vs9.044, respectively, mean\ud difference=−1.291,(95% CI −2.296 to −0.285, p=0.012)).\ud Estimated net plasminogen activator inhibitor type 1\ud antigen release was reduced in the SRT2104 arm versus\ud placebo (mean difference=−38.89 ng/100mL tissue/\ud min, (95%CI −75.47, to –2.305, p=0.038)). There were\ud no differences in other plasma fibrinolytic factors (p>0.05\ud for all). After 28 days, SRT2104 exposure was associated\ud with weight reduction (−0.93 kg (95% CI −1.72 to −0.15),\ud p=0.0236), and a rise in glycated haemoglobin (5 mmol/\ud mol or 0.48% (0.26 to 0.70), p=0.004)\ud Conclusions: In people with T2DM, SRT2104 had\ud inconsistent, predominantly neutral effects on endothelial\ud and fibrinolytic function, and no discernible effect on lipids\ud or platelet function. In contrast, weight loss was induced\ud along with deterioration in glycaemic control, suggestive of\ud potentially important metabolic effects.\ud Clinical trial registration: NCT01031108; Results.

Published
2017

24. SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies.

Author

Hoffmann, Ethan, Nomikos, George G., Kaul, Inder, Raines, Shane, Wald, Jeff, Bullock, Amy, Sankoh, Abdul J., Doherty, James, Kanes, Stephen J., and Colquhoun, Helen

Subjects
*CLINICAL pharmacology, *PHARMACOKINETICS, *DRUG tolerance, *MENTAL depression, *POSTPARTUM depression, *STEROID drugs, *GABA agonists, *SAFETY, *BIOCHEMISTRY, *RESEARCH, *HUMAN research subjects, *STEROIDS, *HETEROCYCLIC compounds, *PHARMACOLOGY, *ORAL drug administration, *RESEARCH methodology, *MEDICAL cooperation, *EVALUATION research, *DRUG administration, *PHENOMENOLOGY, *PLACEBOS, *COMPARATIVE studies, *RANDOMIZED controlled trials, *BLIND experiment, *DOSE-effect relationship in pharmacology, *STATISTICAL sampling, *PSYCHOLOGICAL factors
Abstract

Background: SAGE-217, a novel γ-aminobutyric acid A (GABAA) receptor positive allosteric modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) studies to assess the safety and pharmacokinetics (PK) of SAGE-217 following administration as an oral solution.Methods: In the SAD study, subjects were randomized 6:2 to a single dose of SAGE-217 or placebo. Doses ranged from 0.25 to 66 mg across nine cohorts. In the MAD study, subjects were randomized 9:3 and received SAGE-217 (15, 30, or 35 mg) or placebo once daily for 7 days. In both studies, PK, maximum tolerated dose (MTD; against predetermined criteria), safety, and tolerability were assessed.Results: A total of 108 healthy volunteers enrolled in the studies-72 subjects in the SAD study and 36 subjects in the MAD study. SAGE-217 was orally bioavailable, with a terminal-phase half-life of 16-23 h and a tmax of approximately 1 h. The MTDs for the oral solution of SAGE-217 in the SAD and MAD studies were determined to be 55 and 30 mg daily, respectively. In both studies, SAGE-217 was generally well tolerated, and no serious adverse events (SAEs) were reported. Most AEs were mild, dose-dependent, transient, occurred around the tmax, and related to drug pharmacology.Conclusions: SAGE-217 was generally well tolerated, and its PK profile was well characterized. Based on this profile, SAGE-217 has been advanced into multiple phase II clinical programs and pivotal studies of major depressive disorder and postpartum depression. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

25. Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus

Author

Venkatasubramanian, Sowmya, Noh, Radzi M., Daga, Shruti, Langrish, Jeremy P., Mills, Nicholas L., Waterhouse, Brian R., Hoffmann, Ethan, Jacobson, Eric W., Lang, Ninian N., Frier, Brian M., and Newby, David E.

Abstract

Objective: Arterial stiffness increases with age, and is associated with adverse cardiovascular outcome including increased mortality. The effect of the oral small molecule SIRT1 activator, SRT2104, on arterial stiffness was examined in otherwise healthy cigarette smokers and participants with type 2 diabetes mellitus.\ud \ud Methods: 24 otherwise healthy cigarette smokers and 15 people with stable type 2 diabetes were randomised in a double-blind placebo-controlled crossover trial and received 28 days of oral SRT2104 (2.0 g/day) or matched placebo. Blood pressure was measured using non-invasive oscillatory sphygmomanometry. Pulse wave analysis and velocity were measured using applanation tonometry at baseline and the end of each treatment period. Owing to the small sample size and similar trends for both groups, data for the two groups were pooled (post hoc analysis).\ud \ud Results: Compared to placebo, treatment with SRT2104 was associated with a significant reduction in augmentation pressure (p=0.0273) and a trend towards improvement in the augmentation index and corrected augmentation index (p>0.05 for both). However, no changes were observed in pulse wave velocity and time to wave reflection (p>0.05). Systolic and diastolic blood pressures remained unchanged throughout the study. Treatment by cohort interaction was not significant for any of the pulse wave parameters, suggesting that the response to SRT2104 in otherwise healthy smokers and people with diabetes was consistent.\ud \ud Conclusions: SRT2104 may improve measures of arterial stiffness in otherwise healthy cigarette smokers and in participants with type 2 diabetes. Definitive conclusions are not possible given the small sample size and exploratory nature of this analysis.\ud \ud Trial registration number: NCT01031108.

Published
2016

33. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man

Author

Hoffmann, Ethan, Wald, Jeff, Lavu, Siva, Roberts, John, Beaumont, Claire, Haddad, Jon, Elliott, Peter, Westphal, Christoph, and Jacobson, Eric

Subjects
Enzyme Activation, Male, Thiazoles, Dose-Response Relationship, Drug, Double-Blind Method, Sirtuin 1, Imidazoles, Biological Availability, Humans, Pharmacokinetics, Female
Abstract

SRT2104 is a novel, first-in-class, highly selective small molecule activator of the NAD + dependent deacetylase SIRT1. SRT2104 was dosed to healthy male and female volunteers in a series of phase 1 clinical studies that were designed to elucidate tolerability and pharmacokinetics associated with oral dosing to aid in dose selection for subsequent clinical trials.In the first-in-human study, there was both a single dose phase and 7 day repeat dose phase. Doses used ranged from 0.03 to 3.0 g. A radioactive microtracer study was subsequently conducted to determine systemic clearance, bioavailability and preliminary metabolism, and a crossover study was conducted to determine the effect of gender, formulation and feeding state on SRT2104 pharmacokinetics.SRT2104 was well tolerated in all of these studies, with no serious adverse reactions observed. SRT2104 displayed a dose-dependent, but sub-proportional increase in exposure following single dose and repeated dose administration. Accumulation of three-fold or less occurs after 7 days of repeat dosing. The mean bioavailability was circa 14% and the mean clearance was circa 400 ml min(-1). Although there were no substantial effects on exposure resulting from gender or formulation differences, a notable food effect was observed, manifested as up to four-fold increase in exposure parameters.In the absence of an optimized formulation of SRT2104, the food effect can be used to maximize exposure in future clinical studies. Combined with the good tolerability of all doses demonstrated in these studies, the favourable selectivity profile of SRT2104 allows for the use of this SIRT1 modulator for target validation in the clinic.

Published
2012

34. Neuroactive Steroids. 1. Positive Allosteric Modulators of the (γ-Aminobutyric Acid)AReceptor: Structure–Activity Relationships of Heterocyclic Substitution at C-21

Author

Martinez Botella, Gabriel, primary, Salituro, Francesco G., additional, Harrison, Boyd L., additional, Beresis, Richard T., additional, Bai, Zhu, additional, Shen, Kaisheng, additional, Belfort, Gabriel M., additional, Loya, Carlos M., additional, Ackley, Michael A., additional, Grossman, Scott J., additional, Hoffmann, Ethan, additional, Jia, Shiling, additional, Wang, Jiamiao, additional, Doherty, James J., additional, and Robichaud, Albert J., additional

Published
2015
Full Text
View/download PDF

35. Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric...

Author

Botella, Gabriel Martinez, Salituro, Francesco G., Harrison, Boyd L., Beresis, Richard T., Bai, Zhu, Blanco, Maria-Jesus, Belfort, Gabriel M., Jing Dai, Loya, Carlos M., Ackley, Michael A., Althaus, Alison L., Grossman, Scott J., Hoffmann, Ethan, Doherty, James J., and Robichaud, Albert J.

Published
2017
Full Text
View/download PDF

36. Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers

Author

Venkatasubramanian, Sowmya, primary, Noh, Radzi Mohd, additional, Daga, Shruti, additional, Langrish, Jeremy P., additional, Joshi, Nikhil V., additional, Mills, Nicholas L., additional, Hoffmann, Ethan, additional, Jacobson, Eric W., additional, Vlasuk, George P., additional, Waterhouse, Brian R., additional, Lang, Ninian N., additional, and Newby, David E., additional

Published
2013
Full Text
View/download PDF

38. Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors

Author

Wang, Tao, primary, Lamb, Michelle L., additional, Block, Michael H., additional, Davies, Audrey Molina, additional, Han, Yongxin, additional, Hoffmann, Ethan, additional, Ioannidis, Stephanos, additional, Josey, John A., additional, Liu, Zhong-Ying, additional, Lyne, Paul D., additional, MacIntyre, Terry, additional, Mohr, Peter J., additional, Omer, Charles A., additional, Sjögren, Tove, additional, Thress, Kenneth, additional, Wang, Bin, additional, Wang, Haiyun, additional, Yu, Dingwei, additional, and Zhang, Hai-Jun, additional

Published
2012
Full Text
View/download PDF

39. Évaluation des traits caractéristiques de la psychopathie chez les adolescents délinquants

Author

Atarhouch, N., Hoffmann, Ethan, Adam, Sami, Titeca, J., Stillemans, Édith, Fossion, Pierre, Le Bon, Olivier, Servais, Laurent, Atarhouch, N., Hoffmann, Ethan, Adam, Sami, Titeca, J., Stillemans, Édith, Fossion, Pierre, Le Bon, Olivier, and Servais, Laurent

Abstract

The concept of psychopathy has received many definitions for the first days of psychiatry. Recently, the Hare's Psychopathy Check List Revised has been created. This scale has the advantage to investigate the classically characteristic traits of the syndrome (need of stimulation, lack of culpability, superficial activity, lack of empathy, impassivity) and to point out the early development of behavior disturbances. In the American classification (DSM IV), oppositional and aggressive behavior in child and adolescent is grouped under the Conduct Disorder diagnostic criteria. This trouble appears to be a strong predictive factor of psychopathy in adult. Identifying the high risk factors of evolution to psychopathic personality would allow an earlier intervention and prevention by multisystemic interventions for example. The present study aims to evaluate in what measure characteristic traits of psychopathy in adults are present in severe juvenile offenders and to point out, in a second time, the differences between adolescents meeting the DSM IV criteria for Conduct Disorder and a control population by a dimensional personality inventory. Method - The sample consists in 47 severe juvenile offenders referred for at least 3 months by a Youth Court to a Public Institution for Youth Protection (Belgium, Wauthier-Braine, 1999-2001), who have given an oral contentment and completely fulfilled the Temperament and Character Inventory-TCI. We have collected data about: schooling year by year, number of fails, changes of school; antecedents of oppositional defiant disorder with provocation (ODD, DSM IV criteria); antecedent of Conduct Disorder (CD, DSM IV criteria); penal antecedents (Youth Judge, works of general interest, placements); medico-psychological antecedents (consultation to a psychologist or a psychiatrist, hospitalization, illness, surgical intervention); psychoactive drug use or abuse. We used the TCI - Temperament and Character Inventory. This is a dimensional per, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2004

40. Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway

Author

Ioannidis, Stephanos, primary, Lamb, Michelle L., additional, Wang, Tao, additional, Almeida, Lynsie, additional, Block, Michael H., additional, Davies, Audrey M., additional, Peng, Bo, additional, Su, Mei, additional, Zhang, Hai-Jun, additional, Hoffmann, Ethan, additional, Rivard, Caroline, additional, Green, Isabelle, additional, Howard, Tina, additional, Pollard, Hannah, additional, Read, Jon, additional, Alimzhanov, Marat, additional, Bebernitz, Geraldine, additional, Bell, Kirsten, additional, Ye, Minwei, additional, Huszar, Dennis, additional, and Zinda, Michael, additional

Published
2010
Full Text
View/download PDF

41. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

Author

Thress, Kenneth, primary, MacIntyre, Terry, additional, Wang, Haiyun, additional, Whitston, Dave, additional, Liu, Zhong-Ying, additional, Hoffmann, Ethan, additional, Wang, Tao, additional, Brown, Jeffrey L., additional, Webster, Kevin, additional, Omer, Charles, additional, Zage, Peter E., additional, Zeng, Lizhi, additional, and Zweidler-McKay, Patrick A., additional

Published
2009
Full Text
View/download PDF

42. Impact of gender and estrogen replacement therapy on sleep quality and sleep-related hormone secretion in older adults

Author

Associated Professional Sleep Societies, 15th Annual Meeting (5-10 juin 2001: Chicago, IL, USA), Latta, F, Leproult, Rachel, Hoffmann, Ethan, L'Hermite-Balériaux, Mireille, Van Cauter, Eve, Associated Professional Sleep Societies, 15th Annual Meeting (5-10 juin 2001: Chicago, IL, USA), Latta, F, Leproult, Rachel, Hoffmann, Ethan, L'Hermite-Balériaux, Mireille, and Van Cauter, Eve

Abstract

info:eu-repo/semantics/nonPublished

Published
2001

43. Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases

Author

Wang, Tao, primary, Lamb, Michelle L., additional, Scott, David A., additional, Wang, Haixia, additional, Block, Michael H., additional, Lyne, Paul D., additional, Lee, John W., additional, Davies, Audrey M., additional, Zhang, Hai-Jun, additional, Zhu, Yanyi, additional, Gu, Fei, additional, Han, Yongxin, additional, Wang, Bin, additional, Mohr, Peter J., additional, Kaus, Robert J., additional, Josey, John A., additional, Hoffmann, Ethan, additional, Thress, Ken, additional, MacIntyre, Terry, additional, Wang, Haiyun, additional, Omer, Charles A., additional, and Yu, Dingwei, additional

Published
2008
Full Text
View/download PDF

44. Neuroactive Steroids. 1. Positive Allosteric Modulators of the (?-Aminobutyric Acid)A Receptor: Structure-Activity Relationships of Heterocyclic Substitution at C-21.

Author

Martinez Botella, Gabriel, Salituro, Francesco G., Harrison, Boyd L., Beresis, Richard T., Zhu Bai, Kaisheng Shen, Belfort, Gabriel M., Loya, Carlos M., Ackley, Michael A., Grossman, Scott J., Hoffmann, Ethan, Shiling Jia, Jiamiao Wang, Doherty, James J., and Robichaud, Albert J.

Published
2015
Full Text
View/download PDF

47. Production of ρ+, -, 0 (770), η(550), ω(783) and f2(1270) mesons in {Mathematical expression} neon and ν neon charged current interactions

Author

Wittek, Wolfgang, Aderholz, M, Hantke, Detlev, Hoffmann, Ethan, Katz, Uli U.F., Kern, J., Schmitz, Norbert, Allport, P.P., Cooper-Sarkar, Amanda A.M., Guy, J. G V, Middleton, Robin R.P., Venus, W., Baton, J.P., Neveu, Magella, Berggren, Mikael, Calicchio, Marco, Erriquez, Onofrio, Clayton, E.F. E.F., Mobayyen, M.M. M.M., Coghen, T., Jones, G.T., O'Neale, S., Varvell, Kevin K.E., Marage, Pierre, Willocq, Stéphane, Matsinos, Evangelos, Simopoulou, E., Vayaki, A., Morrison, Douglas R O, Parker, Monique, Wachsmuth, H., Sansum, R.A. R.A., Wells, James, Wittek, Wolfgang, Aderholz, M, Hantke, Detlev, Hoffmann, Ethan, Katz, Uli U.F., Kern, J., Schmitz, Norbert, Allport, P.P., Cooper-Sarkar, Amanda A.M., Guy, J. G V, Middleton, Robin R.P., Venus, W., Baton, J.P., Neveu, Magella, Berggren, Mikael, Calicchio, Marco, Erriquez, Onofrio, Clayton, E.F. E.F., Mobayyen, M.M. M.M., Coghen, T., Jones, G.T., O'Neale, S., Varvell, Kevin K.E., Marage, Pierre, Willocq, Stéphane, Matsinos, Evangelos, Simopoulou, E., Vayaki, A., Morrison, Douglas R O, Parker, Monique, Wachsmuth, H., Sansum, R.A. R.A., and Wells, James

Abstract

The production of the meson resonances ρ{variant}(770) (all three charge states), η(550), ω(783) and f2(1270) in {Mathematical expression} Ne and ν Ne charged current interactions is investigated in a bubble chamber experiment with BEBC at CERN. Except for the f2, the main features of resonance production are reasonably well described by the Lund model, although the average resonance multiplicities are overestimated by the model by (67±30)%. The average multiplicities of all resonances, including the f2, are well reproduced by a semiempirical model, whose parameters were determined from hadron interaction data. © 1989 Springer-Verlag., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1989

48. Production of π0 mesons and charged hadrons in {Mathematical expression} neon and ν neon charged current interactions

Author

Wittek, Wolfgang, Aderholz, M, Hoffmann, Ethan, Katz, Uli U.F., Kern, J., Schmitz, Norbert, Allport, P.P., Cooper-Sarkar, Amanda A.M., Guy, J. G V, Venus, W., Armenise, Nicola, Calicchio, Marco, Erriquez, Onofrio, Baton, J.P., Kasper, Penelope, Neveu, Magella, Berggren, Mikael, Hulth, Per Olof, Bullock, Frederick, Fitch, P.J., Clayton, E.F. E.F., Coghen, T., Giannakopoulos, N., Matsinos, Evangelos, Simopoulou, E., Vayaki, A., Jones, G.T., Varvell, Kevin K.E., Klein, Harold, Morrison, Douglas R O, Parker, Monique, Wachsmuth, H., Marage, Pierre, Wittek, Wolfgang, Aderholz, M, Hoffmann, Ethan, Katz, Uli U.F., Kern, J., Schmitz, Norbert, Allport, P.P., Cooper-Sarkar, Amanda A.M., Guy, J. G V, Venus, W., Armenise, Nicola, Calicchio, Marco, Erriquez, Onofrio, Baton, J.P., Kasper, Penelope, Neveu, Magella, Berggren, Mikael, Hulth, Per Olof, Bullock, Frederick, Fitch, P.J., Clayton, E.F. E.F., Coghen, T., Giannakopoulos, N., Matsinos, Evangelos, Simopoulou, E., Vayaki, A., Jones, G.T., Varvell, Kevin K.E., Klein, Harold, Morrison, Douglas R O, Parker, Monique, Wachsmuth, H., and Marage, Pierre

Abstract

The average multiplicities of charged hadrons and of π+, π- and π0 mesons, produced in {Mathematical expression}Ne and νNe charged current interactions in the forward and backward hemispheres of the W±-nucleon center of mass system, are studied with data from BEBC. The dependence of the multiplicities on the hadronic mass (W) and on the laboratory rapidity (yLab) and the energy fraction (z) of the pion is also investigated. Special care is taken to determine the π0 multiplicity accurately. The ratio of average π multiplicities {Mathematical expression} is consistent with 1. In the backward hemisphere {Mathematical expression} is positively correlated with the charged multiplicity. This correlation, as well as differences in multiplicities between {Mathematical expression} and {Mathematical expression}, {Mathematical expression} scattering, is attributed to reinteractions inside the neon nucleus of the hadrons produced in the initial {Mathematical expression} interaction. © 1988 Springer-Verlag., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1988

50. Diorganotin(IV) derivatives of 2,6-pyridine dicarboxylic acid: synthesis, spectroscopic characterization, X-ray structure analysis, in vitro and in vivo anti-tumour activity

Author

Gielen, Marcel, Joosen, Étienne, Mancilla, Teresa Mancilla, Jurkschat, K., Willem, Rudolph, Roobol, C., Bernheim, Jan, Atassi, Ghanem, Huber, F. A M, Hoffmann, Ethan, Preut, H., Mahieu, Bernard, Gielen, Marcel, Joosen, Étienne, Mancilla, Teresa Mancilla, Jurkschat, K., Willem, Rudolph, Roobol, C., Bernheim, Jan, Atassi, Ghanem, Huber, F. A M, Hoffmann, Ethan, Preut, H., and Mahieu, Bernard

Abstract

info:eu-repo/semantics/published

Published
1987

Catalog

Books, media, physical & digital resources
See catalog results